With healthcare at a key crossroads of policy, technology, and science, Sanofi CEO Paul Hudson shares the Big Pharma’s ...

In today’s Pharmaceutical Executive Daily, we cover Lilly’s orforglipron as a prime candidate for FDA fast-track approval, ...

FDA warns major pharmaceutical companies to improve transparency in drug advertising, addressing misleading claims and ...

As drugmakers navigate an increasingly complex terrain of scientific and digital influence, the ability to accurately ...

Eli Lilly's Orforglipron shows superior results in glycemic control and weight loss compared to oral semaglutide in recent ...

VarmX announced its partnership with CSL, supporting the development of its lead asset VMX-C001, along with entering into an ...

He has held appointments as Visiting Professor or Distinguished Lecturer at Princeton University, Vanderbilt University, the ...

Outlining the key touchpoints for embracing change and opportunity in the “messy, tough—and fun” R&D-to-commercial transition ...

Novo Nordisk's Rybelsus gains EU approval for cardiovascular benefits, enhancing treatment options for type 2 diabetes and ...

Ryan Quigley, CEO of Inizio, discusses how his experience as Chief Operating Officer shaped his journey to CEO.

R-DXd has previously shown promising clinical results in platinum-resistant ovarian, peritoneal, and fallopian tube cancers.

The new administration has a different perspective of vaccines than the previous administration, causing confusion with the ...